Outsourcing STREAM

  1. How To Generate A High-Producing Cell Line In Fast-Track Mode 12/11/2019

    Cell line development processes can be quite time consuming and labor intensive. When our clients have a very challenging timeline, we can begin process development in parallel with cell line development, further accelerating timelines. What are the risks and how do you minimize risk?

  2. Scale Your Process Directly From 3L To 2,000L Blindfolded 12/11/2019

    In the biotech industry, you need to move quickly and use resources efficiently to advance a drug candidate into the clinic and ultimately onto the market. Being able to quickly produce a batch at the right time and at the right size is essential to support development and get to the finish line faster. We developed a strategy to enable a direct, efficient and robust tech transfer of a monoclonal antibody production process from a 3L bioreactor to 2000L without the need for any intermediate volumes.

  3. Collaboration & Expertise, The Keys To Efficiency And Scalability Across All Modalities 7/8/2022

    View this video and discover our global vaccine capabilities from process development to full-scale GMP-manufacturing and in all modalities.

  4. Factors Which Impact mAb Process Scale-Up 9/7/2021

    Thinking about your mAb scale-up processes early on can help avoid common pitfalls. Cytiva’s Fast Trak scientists discuss factors that can influence a successful scale-up outcome.

  5. Release Your Gene Therapy With Confidence 7/20/2021

    You are developing a cell or gene therapy and now you need to deliver it quickly to patients. But first you must make sure it's safe and effective. That's where we come in. Our experts can draw a testing strategy for your specific product, process, and goals.

  6. Commercial Readiness with Orca Bio's Dan Kirby 9/14/2023

    Orca Bio's Dan Kirby has played a hand in prepping more than a few approved biologic therapeutic candidates for commercialization. Equally important, he knows firsthand what makes or breaks post-approval commercial efforts, having played virtually every role there is to play in drug sales and marketing.

  7. Increasing The Reach Of Cell And Gene Therapies 4/29/2021

    The cell and gene therapy industry is rapidly evolving from the perspective of “can we commercialize this class of therapeutics?” to “how do we reach patients who need these therapies?”. However, the promise of these biologics can only be realized if the industry approaches manufacturing parity with monoclonal antibodies. A mixture of innovation and brute-force streamlining is needed to create viable cell and gene therapy templates. In this video, we discuss how upstream process optimization is ripe for innovative approaches.

  8. Thermo Fisher Scientific North America Single-Use Technologies Capacity Expansion 3/2/2021

    Thermo Fisher Scientific is expanding our single-use manufacturing network globally. Some of the largest investments are taking place at our existing Logan, Utah, and Millersburg, Pennsylvania, sites. We are adding space for clean rooms for the manufacturing and assembly of Thermo Scientific BioProcess Containers and fluid transfer assemblies, investing in 2D and 3D chamber manufacturing equipment, and harmonizing our quality systems and processes.

  9. Discovering A Unique Multimillion Euro Nanotechnology Facility 10/25/2024

    Dr. David Rowe, Head of Manufacturing at Nanoform, provides an overview of Nanoform's manufacturing capabilities and introduces a new, state-of-the-art nanotechnology facility.

  10. Increase The Titer Of A Difficult To Express Molecule 12/11/2019

    What happens if you have a promising molecule but can’t engineer a cell line to deliver the titer needed to support clinical development?  A low process titer may render the molecule, such as an antibody, too costly to manufacture and unsuitable for continued investment. Learn how our client achieved a nearly 4-fold titer increase.